AIM VCTs company stories: Ergomed
Pioneering treatments for the world’s rarest diseases
For over 20 years, Ergomed has provided specialised solutions to the pharmaceutical industry throughout the
trial and development stage of new drugs.
Expanding global pharmaceutical solutions
For over 20 years, Ergomed has provided specialised solutions to the pharmaceutical industry throughout the trial and development stage of new drugs.
The company also has a co-development arm where it partners with pharma companies and benefits from revenue streams of drugs already on the market, adding to its growth potential.
Ergomed continues to expand its global impact in the market, currently operating in over 100 countries and providing solutions for over 180 clients ranging from top 10 pharmaceutical organisations to small and mid-sized drug development companies.
Octopus AIM VCT risks
Please remember that the value of an investment in the Octopus AIM VCTs, and any income from it, can fall as well as rise. Investors may not get back the full amount they invest.
Tax treatment depends on individual circumstances and may change in the future. Tax reliefs depend on the VCT maintaining its qualifying status.
VCT shares could fall or rise in value more than shares listed on the main market of the London Stock Exchange. They may also be harder to sell.
Investors should only subscribe for shares on the basis of information contained in the prospectus and Key Information Documents (KIDs), available on the AIM VCT product page.
More for the AIM VCTs
Supplying a wide range of materials to the construction industry.
Leading online retailer of musical instruments.
Contact our team
Got a question?
Call us at 0800 316 2067